This is an evolutionary step forward. At MindWalk, we're redefining biologics research through advanced AI, powered by our LensAI™ platform at the core. Discover how we're bringing biology to the future: https://t.co/TKEickwHfx 🇺🇸 #NASDAQ: $HYFT

Central to our journey in redefining the industry through #AI solutions is LensAI™, our platform engineered to make drug discovery more #efficient, #precise, and #biology-driven. Explore its potential: https://t.co/2OgP7Z8r5l 🇺🇸 #NASDAQ: $HYFT

🗞️ INDUSTRY NEWS UPDATE: A new review highlights #AI’s potential to improve heart #drugdevelopment, calling for a major shift in discovery, testing, and development through AI, #omics, and #bigdata. Read the full article: https://t.co/IrBoMgif0a 🇺🇸 #NASDAQ: $HYFT

MindWalk AI, our new unified brand for IPA and its subsidiaries, is propelling the next generation of biologics discovery and development. Get the full picture: https://t.co/2OgP7Z8r5l 🇺🇸 #NASDAQ: $HYFT

Modernizing #healthcare means delivering better care. Organizations that succeed in this transformation see an average ROI of 124%, driven by stronger outcomes and streamlined operations. AI is one of the drivers of this progress. MindWalk AI connects #AI, #data, and #labscience

𝗔𝗠𝗗 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁𝘀 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗶𝗻 𝗮𝗻 𝗔𝗜-𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝘆 Our partner AMD featured MindWalk in a new case study, showcasing how advanced AI and next-generation compute are accelerating biologics

🗞️ INDUSTRY NEWS UPDATE: As industry pressures mount and expectations evolve, #healthcare is embracing #AI to streamline operations and prioritize patient care. Access the full article: https://t.co/KtBHO5qnrm 🇺🇸 #NASDAQ: $HYFT

The potential of #AI to transform healthcare is limitless, from precise detection to groundbreaking #drugdiscovery. At MindWalk, we’re proud to be part of that change, pushing the boundaries of #biologicsresearch through our advanced AI portfolio. Full article:

Where is AI headed next, and are we on the same page? Frédéric Chabot, our Head of Corporate Development, joined fellow industry leaders on December 4 for @_investortv's live panel, “The AI Wave: Opportunities, Disruptions, and What Comes Next,” to explore what’s ahead. Missed

💡 Michael Yee, Senior Biotech Analyst at @Jefferies, discusses how AI is shaping drug discovery and development, and what this could mean for the future of biotech innovation. Watch: https://t.co/pSlBHKnrnW 🇺🇸 #NASDAQ: $HYFT

𝗛𝗮𝗽𝗽𝘆 𝗵𝗼𝗹𝗶𝗱𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝘁𝗲𝗮𝗺. As the year wraps up, we want to thank the clients, partners, and collaborators we’ve had the chance to work alongside. Cheers to the year ahead. We’re glad to be in it with you. 𝗪𝗶𝘀𝗵𝗶𝗻𝗴 𝘆𝗼𝘂 𝗮

🗞️ INDUSTRY NEWS UPDATE: #AItools are improving traditional #drugdiscovery methods to speed up the process. Read the full article to understand the benefits and challenges of this emerging trend: https://t.co/6d5WimUU1w 🇺🇸 #NASDAQ: $HYFT

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗥𝗲𝗰𝗼𝗿𝗱 𝗚𝗿𝗼𝘄𝘁𝗵 𝗮𝗻𝗱 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗼𝗻 𝗜𝘁𝘀 𝗔𝗜 𝗔𝘀𝘀𝗲𝘁 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 Join today's call to hear more about the record financial performance and key strategic highlights.

The global #AI in #drugdiscovery market is projected to grow at an estimated CAGR of 37.67% through 2032, driven by strong R&D investments and other factors. We're taking one revolutionary step forward: advancing from epitope mapping to de novo molecular design and in silico

⏪ IN CASE YOU MISSED IT: It’s only a matter of time before AI transforms healthcare, and we're part of this transformation. In October, President and CEO Dr. Jennifer Bath joined #StockstoWatch to share updates on our journey, from our rebranding to what’s ahead. Replay:

🗞️ INDUSTRY NEWS UPDATE: Researchers from the Wadhwani School of Data Science and Artificial Intelligence (WSAI), IIT Madras, and The Ohio State University have developed an AI framework that can significantly shorten the early phases of #drugdevelopment. Read:

#AI is laying a new foundation in healthcare, with 22% of #healthcare organizations now implementing domain-specific #AItools, marking a 7x increase over 2024. At MindWalk, we’re tackling challenges in drug discovery with an AI-driven approach. Learn more:

📩 Want to stay in the loop? Get your dose of #AI insights, project updates, and investor highlights through our #newsletter. Sign up: https://t.co/WCclZK6EM5 🇺🇸 #NASDAQ: $HYFT

Check out our progress: https://t.co/YJTCW8e80x

We're pioneering the future of scalable, AI-powered #drugdiscovery. 🇺🇸 #NASDAQ: $HYFT